Harmonizing tradition and technology: Liposomal nanocarriers unlocking the power of natural herbs in Traditional Chinese Medicine

Abstract

Natural herbs demonstrate significant therapeutic potential in managing chronic and complex diseases; however, their clinical application faces limitations due to low bioavailability, instability, toxicity, and herb-drug interactions. Furthermore, insufficient standardized evidence and global acceptance impede their widespread adoption. Liposomes, nanocarriers consisting of a phospholipid bilayer enclosing an aqueous core, present a promising approach for enhancing the pharmacokinetics and therapeutic efficacy of herbal compounds. These adaptable systems can encapsulate both hydrophilic and hydrophobic agents, enabling targeted drug delivery and enhanced stability. Moreover, liposomes can be modified to carry diagnostic and imaging agents, enabling precise disease detection and monitoring. While liposomes offer potential as an innovative delivery technology for herbal remedies, their application in Traditional Chinese Medicine (TCM) remains relatively unexplored. TCM, with its holistic, energy-based approach to health and organ function, presents distinct challenges regarding formulation and delivery. This review examines the therapeutic potential of herbal medicines, emphasizing how liposomes address delivery challenges within the TCM framework. It also investigates the integration of TCM with Western medical practices, demonstrating how liposomal systems may bridge these approaches. The review analyzes key formulation techniques for TCM-loaded liposomes, particularly the microfluidic method, which demonstrates superior control over particle size and encapsulation efficiency compared to conventional methods. The analysis addresses barriers to integrating liposomal delivery systems with TCM, including physicochemical properties, scalability issues, and regulatory challenges. Finally, this review provides strategic recommendations for overcoming these obstacles and identifies future research directions to maximize the potential of liposomal technology in enhancing TCM therapies.

Keywords

Combination therapy / Drug delivery / Herbal medicine / Liposomes / Microfluidics / Natural medicine / Regenerative medicine / Traditional Chinese medicine

References

[1] Teng L, Zu Q, Li G, et al. Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol. 2016; 9(9):1225-1233. https://doi.org/10.1080/17512433.2016.1195263.

[2] Sammons HM, Gubarev MI, Krepkova LV, et al. Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. Expert Rev Clin Pharmacol. 2016; 9(8):1117-1127. https://doi.org/10.1080/17512433.2016.1189326.

[3] Tang P, Huang D, Zheng KX, et al. Thirteen new peptaibols with antimicrobial activities from Trichoderma sp[J]. Chin J Nat Med. 2023, 21(11): 868-880.

[4] Zhang J, Zhang Z, Wang Z, et al. Targeted trace ingredients coupled with chemometric analysis for consistency evaluation of Panax notoginseng saponins injectable formulations. Chin J Nat Med. 2023; 21(8):631-640. https://doi.org/10.1016/S1875-5364(23)60396-6.

[5] Zhang X, Qiu H, Li C, et al. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021; 15(5):283-298. https://doi.org/10.5582/bst.2021.01318.

[6] Kumar S, Mittal A, Babu D, et al. Herbal medicines for diabetes management and its secondary complications. Curr Diabetes Rev. 2021; 17(4):437-456. https://doi.org/10.2174/1573399816666201103143225.

[7] Li XT, Zhou JC, Zhou Y, et al. Pharmacological effects of Eleutherococcus senticosus on the neurological disorders. Phytother Res. 2022; 36(9):3490-3504. https://doi.org/10.1002/ptr.7555.

[8] Dai YJ, Wan SY, Gong SS, et al.Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19. Chin J Nat Med. 2020; 18(12):881-889. https://doi.org/10.1016/S1875-5364(20)60031-0.

[9] Tahir ul QM, Alqahtani SM, Alamri MA, et al. Structural basis of SARS-CoV-2 3CL^pro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020; 10(4):313-319. https://doi.org/10.1016/j.jpha.2020.03.009.

[10] Bharat Bhushan. Encyclopedia of Nanotechnology. Springer, 2016, 1802-1808.

[11] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al.Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1):1-9. https://doi.org/10.1186/1556-276X-8-1.

[12] Brambilla D, Luciani P, Leroux JC. Breakthrough discoveries in drug delivery technologies: the next 30 years. J Control Release. 2014; 190:9-14. https://doi.org/10.1016/j.jconrel.2014.03.056.

[13] NIC. Doxorubicin Hydrochloride Liposome. https://www.cancer.gov/about-cancer/treatment/drugs/doxorubicin-hydrochloride-liposome#.

[14] Caracciolo G. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona. Nanoscale. 2018; 10(9):4167-4172. https://doi.org/10.1039/C7NR07450F.

[15] Sun R, Dai J, Ling M, et al. Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine. J Nanobiotechnology. 2022; 20(1):1-16. https://doi.org/10.1186/s12951-021-01184-w.

[16] Zheng X, Wu F, Lin X, et al. Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine. Drug Deliv. 2018; 25(1):398-416. https://doi.org/10.1080/10717544.2018.1431980.

[17] Gao L, Zhang L, He F, et al. Surfactant-assisted rapid-release liposomal strategies enhance the antitumor efficiency of bufalin derivative and reduce cardiotoxicity. Int J Nanomed. 2021; 16:3581-3598. https://doi.org/10.2147/IJN.S313153.

[18] Liang J, Gao C, Zhu Y, et al. Natural brain penetration enhancer-modified albumin nanoparticles for glioma targeting delivery. ACS Appl Mater. 2018; 10(36):30201-30213. https://doi.org/10.1021/acsami.8b11782.

[19] Lin Q, Qu M, Patra HK, et al. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer. J Ethnopharmacol. 2020;247:112283. https://doi.org/10.1016/j.jep.2019.112283.

[20] Kang S, Duan W, Zhang S, et al. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics. 2020; 10(10):4308-4322. https://doi.org/10.7150/thno.41322.

[21] Zhao Q, Sun X, Wu B, et al. Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma. J Nanobiotechnol. 2021; 19(1):8. https://doi.org/10.1186/s12951-020-00738-8.

[22] Wang X, Wang Q, Liu Z, et al. Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes. J Pharma Pharmacol. 2017; 69(6):625-632. https://doi.org/10.1111/jphp.12692.

[23] Sun X, Wei J, Lyu J, et al. Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis. J Nanobiotechnol. 2019; 17(1):1-16. https://doi.org/10.1186/s12951-018-0433-3.

[24] Giulimondi F, Digiacomo L, Pozzi D, et al. Interplay of protein corona and immune cells controls blood residency of liposomes. Nat Commun. 2019; 10(1):1-11. https://doi.org/10.1038/s41467-018-07882-8.

[25] Wong MY, Chiu GNC. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine. 2011; 7(6):834-840. https://doi.org/10.1016/j.nano.2011.02.001.

[26] Hu C, Jia W. Therapeutic medications against diabetes: what we have and what we expect. Adv Drug Deliv Rev. 2019; 139:3-15. https://doi.org/10.1016/j.addr.2018.11.008.

[27] Liu Y, Feng N. Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM). Adv Colloid Interface Sci. 2015; 221:60-76. https://doi.org/10.1016/j.cis.2015.04.006.

[28] Fu FS, Cheng CW, Zhang L, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med. 2016; 22:73-79. https://doi.org/10.1007/s11655-015-2121-6.

[29] Gu W, Luo S. A study on the translation of terms in The Spring and Autumn of Lv Buwei. China Terminol. 2014; 16(2):30-33.

[30] Zheng BC. A pioneer in establishing the tradition of keeping case records. J Tradit Chin Med. 1987; 7(3):231-232.

[31] Chen KJ, Xie YH, Liu Y. Profiles of traditional Chinese medicine schools. Chin J Integr Med. 2012; 18(7):534-538. https://doi.org/10.1007/s11655-012-1147-2.

[32] Fu L. Medical missionaries to China and the reformation of anatomy. J Med Biogr. 2016; 24(2):169-180. https://doi.org/10.1177/0967772014532894.

[33] Sun DZ, Li SD, Liu Y, et al. Differences in the origin of philosophy between Chinese medicine and western medicine: exploration of the holistic advantages of Chinese medicine. Chin J Integr Med. 2013; 19(9):706-711. https://doi.org/10.1007/s11655-013-1435-5.

[34] Hock FJ, Gralinski MR. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, 2020, 2: 455-482.

[35] Zhao F, Yang Z, Wang N, et al.Traditional Chinese medicine and western medicine share similar philosophical approaches to fight COVID-19. Aging Dis. 2021; 12(5):1162-1168. https://doi.org/10.14336/AD.2021.0512.

[36] NCI dictionary of cancer terms - NCI.Definition of western medicine. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/western-medicine.

[37] Matos LC, Machado JP, Monteiro FJ, et al. Understanding traditional Chinese medicine therapeutics: an overview of the basics and clinical applications. Healthcare. 2021; 9(3):257. https://doi.org/10.3390/healthcare9030257.

[38] Parambath A. Engineering of Biomaterials for Drug Delivery Systems. Elsevier, 2018: 255-272

[39] Rakesh K. Tekade. Basic Fundamentals of Drug Delivery. 2019: 651-684.

[40] Pinot M, Vanni S, Pagnotta S, et al. Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science. 2014; 345(6197):693-697. https://doi.org/10.1126/science.1255288.

[41] Nakhaei P, Margiana R, Bokov DO, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol. 2021;9:748.

[42] Nsairat H, Khater D, Sayed U, et al. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022; 8(5):e09394. https://doi.org/10.1016/j.heliyon.2022.e09394.

[43] Sun X, Wei J, Lyu J, et al. Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis. J Nanobiotechnol. 2019; 17(1):10. https://doi.org/10.1186/s12951-019-0447-5.

[44] Ma YJ, Liu SF, Zhou QF, et al. Approved drugs and natural products at clinical stages for treating Alzheimer’s disease. Chin J Nat Med. 2024; 22(8):699-710. https://doi.org/10.1016/S1875-5364(24)60606-0.

[45] Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571. https://doi.org/10.1016/j.ijpharm.2021.120571.

[46] Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022; 27(4):1372. https://doi.org/10.3390/molecules27041372.

[47] Huang Y, Zhao Y, Liu F, et al. Nano traditional Chinese medicine: current progresses and future challenges. Curr Drug Targets. 2015; 16(13):1548-1562. https://doi.org/10.2174/1389450116666150309122334.

[48] Emami S, Azadmard-Damirchi S, Peighambardoust SH, et al. Liposomes as carrier vehicles for functional compounds in food sector. J Exp Nanosci. 2016; 11(9):737-759. https://doi.org/10.1080/17458080.2016.1148273.

[49] Wang J, Kong L, Guo RB, et al. Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer’s disease. Drug Deliv. 2022; 29(1):1648-1662. https://doi.org/10.1080/10717544.2022.2072543.

[50] Wang Y, Ying X, Xu H, et al. The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals. Int J Nanomed. 2017; 12:1369-1384. https://doi.org/10.2147/IJN.S124276.

[51] Song JW, Liu YS, Guo YR, et al. Nano-liposomes double loaded with curcumin and tetrandrine: preparation, characterization, hepatotoxicity and anti-tumor effects. Int J Mol Sci. 2022; 23(12):6858. https://doi.org/10.3390/ijms23126858.

[52] Otake K, Shimomura T, Goto T, et al. Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir. 2006; 22(6):2543-2550. https://doi.org/10.1021/la051654u.

[53] Gouda A, Sakr OS, Nasr M, et al. Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications. J Drug Deliv Sci Technol. 2021;61:102174. https://doi.org/10.1016/j.jddst.2020.102174.

[54] Song J, Shi F, Zhang Z, et al. Formulation and evaluation of celastrol-loaded liposomes. Molecules. 2011; 16(9):7880-7892. https://doi.org/10.3390/molecules16097880.

[55] Nie C, Shaw I, Chen C. Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: a review. J Pharm Anal. 2023; 13(12):1429-1451. https://doi.org/10.1016/j.jpha.2023.08.009.

[56] Leyva-Porras C, Cruz-Alcantar P, Espinosa-Solís V, et al. Applications of differential scanning calorimetry in the study of the liposomes encapsulating traditional Chinese medicine. Polymers (Basel). 2019; 12(1):5. https://doi.org/10.3390/polym12010005.

[57] Carugo D, Bottaro E, Owen J, et al. Liposome production by microfluidics: potential and limiting factors. Sci Rep. 2016; 6(1):1-15. https://doi.org/10.1038/s41598-016-0001-8.

[58] Gupta A, Panigrahi PK. Alternating current coaxial electrospray for micro-encapsulation. Exp Fluids. 2020; 61(2):1-22.

[59] Whiteley Z, Ho HMK, Gan YX, et al. Microfluidic synthesis of protein-loaded nanogels in a coaxial flow reactor using a design of experiments approach. Nanoscale Adv. 2021; 3(7):2039-2055. https://doi.org/10.1039/D0NA01051K.

[60] Lou G, Anderluzzi G, Woods S, et al. A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: formulation, cellular uptake and biodistribution investigations. Eur J Pharm Biopharm. 2019; 143:51-60. https://doi.org/10.1016/j.ejpb.2019.08.013.

[61] Yu B, Lee RJ, Lee LJ. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129-141.

[62] Lou G, Anderluzzi G, Woods S, et al. A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: formulation, cellular uptake and biodistribution investigations. Eur J Pharm Biopharm. 2019; 1(43):51-60.

[63] Shah VM, Nguyen DX, Patel P, et al. Liposomes produced by microfluidics and extrusion: a comparison for scale-up purposes. Nanomedicine. 2019; 18:146-156. https://doi.org/10.1016/j.nano.2019.02.019.

[64] Van Swaay D, Demello A.Microfluidic methods for forming liposomes. Lab Chip. 2013; 13(5):752-767. https://doi.org/10.1039/c2lc41121k.

[65] Duncanson WJ, Lin T, Abate AR, et al. Microfluidic synthesis of advanced microparticles for encapsulation and controlled release. Lab Chip. 2012; 12(12):2135-2145. https://doi.org/10.1039/c2lc21164e.

[66] Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016; 23(9):3319-3329. https://doi.org/10.1080/10717544.2016.1177136.

[67] Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015; 200:138-157. https://doi.org/10.1016/j.jconrel.2014.12.030.

[68] Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018; 19(1):195. https://doi.org/10.3390/ijms19010195.

[69] Lee Y, Thompson DH.Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 9(5):10.1002.

[70] Shi G, Yang C, Wang Q, et al. Traditional Chinese medicine compound-loaded materials in bone regeneration. Front Bioeng Biotechnol. 2022;10:851561. https://doi.org/10.3389/fbioe.2022.851561.

[71] Putnam SE, Scutt AM, Bicknell K, et al. Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res. 2007; 21(2):99-112. https://doi.org/10.1002/ptr.2030.

[72] Liu M, Li Y, Yang ST. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells. J Tissue Eng Regen Med. 2017; 11(1):276-284. https://doi.org/10.1002/term.1911.

[73] Song JE, Tripathy N, Lee DH, et al. Quercetin inlaid silk fibroin/hydroxyapatite scaffold promotes enhanced osteogenesis. ACS Appl Mater. 2018; 10(39):32955-32964. https://doi.org/10.1021/acsami.8b08119.

[74] Zhu J, Liu Y, Chen C, et al. Cyasterone accelerates fracture healing by promoting MSCs migration and osteogenesis. J Orthop Translat. 2021; 28:28-38. https://doi.org/10.1016/j.jot.2020.11.004.

[75] Lu Q, Jiang JG. Chemical metabolism of medicinal compounds from natural botanicals. Curr Med Chem. 2012; 19(11):1682-1705. https://doi.org/10.2174/092986712799945076.

[76] Li H, Wu R, Yu H, et al. Bioactive herbal extracts of traditional Chinese medicine applied with the biomaterials: for the current applications and advances in the musculoskeletal system. Front Pharmacol. 2021;12:778041. https://doi.org/10.3389/fphar.2021.778041.

[77] Li HM, Ye ZH, Zhang J, et al. Clinical trial with traditional Chinese medicine intervention “tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment” for chronic hepatitis B-associated liver failure. World J Gastroenterol. 2014; 20(48):18458-1865. https://doi.org/10.3748/wjg.v20.i48.18458.

[78] Zhang F, Wang F, Liang B, et al. Liver regeneration in traditional Chinese medicine. Regen Med Res. 2020;8:1. https://doi.org/10.1051/rmr/190003.

[79] Zhao BB, Li HM, Gao X, et al. The herbal compound “diwu Yanggan” modulates liver regeneration by affecting the hepatic stem cell microenvironment in 2-acetylaminofluorene/partial hepatectomy rats. Evid-Based Compl Alt. 2015;2015:468303.

[80] Dudics S, Langan D, Meka RR, et al. Natural products for the treatment of autoimmune arthritis: their mechanisms of action, targeted delivery, and interplay with the host microbiome. Int J Mol Sci. 2018; 19(9):2508. https://doi.org/10.3390/ijms19092508.

[81] Cui MD, Pan ZH, Pan LQ. Danggui Buxue extract-loaded liposomes in thermosensitive gel enhance in vivo dermal wound healing via activation of the VEGF/PI3K/Akt and TGF-β/Smads signaling pathway. Evid-Based Compl Alt. 2017;2017:8407249. https://doi.org/10.1155/2017/8407249.

[82] Dou G, Chen Y, Fu H. Application of modern molecular biotechnology in identification of traditional Chinese medicine. IJBLST. 2022; 1(1):27-29. https://doi.org/10.54097/ijbls.v1i1.2276.

[83] Wang W, Zhao H, Chen J, et al. Bridge the gap between syndrome in traditional Chinese medicine and proteome in Western medicine by unsupervised pattern discovery algorithm[C]. 2008 IEEE International Conference on Networking, Sensing and Control, Sanya, China. 2008, 745-750.

[84] Liu P. Development of the integrated TCM hepatology with Western medicine. Chin J Integr Med. 2003; 1(2):81-83. https://doi.org/10.3736/jcim20030201.

[85] Zhang K, Tian M, Zeng Y, et al.The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19. Complement Ther Med. 2020;52:102473. https://doi.org/10.1016/j.ctim.2020.102473.

[86] Mao J, Hou Y, Shang H, et al. Study on the evaluation of the clinical effects of traditional chinese medicine in heart failure by complex intervention: protocol of SECETCM-HF. Trials. 2009;10:122. https://doi.org/10.1186/1745-6215-10-122.

[87] Lin SI, Tsai TH, Chou YJ, et al. Characteristics associated with utilization of asthma-related traditional Chinese medicine services among asthma children in Taiwan: a nationwide cohort study. Evid-Based Compl Alt. 2015;2015:108961.

[88] Zhou JC, Fan QL, Cai XY, et al. Ginkgo biloba extract protects against depression-like behavior in mice through regulating gut microbial bile acid metabolism. Chin J Nat Med. 2023; 21(10):745-758.

[89] Wang W J, Zhang T. Integration of traditional Chinese medicine and Western medicine in the era of precision medicine. J Integr Med. 2017; 15(1):1-7. https://doi.org/10.1016/S2095-4964(17)60314-5.

[90] Chan N, Li S, Perez E. Interactions between Chinese nutraceuticals and Western medicines. Nutraceuticals. 2016;:875-882.

[91] Nakai S, Kawakita T, Nagasawa H, et al. Thymus-dependent effects of a traditional Chinese medicine, Ren-shen-yang-rong-tang (Japanese name; Ninjin-youei-to), in autoimmune MRL/MP-lpr/lpr mice. Int J Immunopharmacol. 1996; 18(4):271-279. https://doi.org/10.1016/0192-0561(96)84507-3.

[92] Lim JW, Chee SX, Wong WJ, et al. Traditional Chinese medicine: herb-drug interactions with aspirin. Singapore Med J. 2018; 59(5):230-239. https://doi.org/10.11622/smedj.2018051.

[93] O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX^TM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15(3):440-449. https://doi.org/10.1093/annonc/mdh097.

[94] Yechezkel (Chezy) Barenholz. Handbook of Harnessing Biomaterials in Nanomedicine[M]. Stanford Publishing, 2021: 463-528.

[95] Barenholz Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2):117-134. https://doi.org/10.1016/j.jconrel.2012.03.020.

[96] Yan W, Leung SSY, To KKW. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine. 2019; 15(3):303-318.

[97] Guo C, Su Y, Wang H, et al. A novel saponin liposomes based on the couplet medicines of Platycodon grandiflorum-Glycyrrhiza uralensis for targeting lung cancer. Drug Deliv. 2022; 29(1):2743-2750. https://doi.org/10.1080/10717544.2022.2112997.

[98] Wei Y, Guo J, Zheng X, et al. Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes. Int J Nanomed. 2014; 9(1):3623-3360.

[99] Daraee H, Etemadi A, Kouhi M, et al. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016; 44(1):381-391. https://doi.org/10.3109/21691401.2014.953633.

[100] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019; 575(7782):299-309. https://doi.org/10.1038/s41586-019-1730-1.

[101] Zhang J, Li X, Huang L. Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. Adv Drug Deliv Rev. 2020; 154:245-273. https://doi.org/10.1016/j.addr.2020.05.006.

[102] Cai P, Qiu H, Qi F, et al. The toxicity and safety of traditional Chinese medicines: please treat with rationality. Biosci Trends. 2019; 13(5):367-373. https://doi.org/10.5582/bst.2019.01244.

[103] Bel L, Saunders DN, Ranson M, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018; 277:1-13. https://doi.org/10.1016/j.jconrel.2018.02.040.